Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “VANDA PHARMACEUTICALS INC.”

96 pharma patents match "VANDA PHARMACEUTICALS INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 96
Index total 30,257
Page 4 / 4

Quick answer

This filtered view shows 96 pharmaceutical patents matching "VANDA PHARMACEUTICALS INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

96 results for “VANDA PHARMACEUTICALS INC.” · 30,257 patents in full index Clear search

  1. US 9617203

    Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide

    VANDA PHARMACEUTICALS INC. · Granted Apr 11, 2017 · Expires Apr 6, 2037

    granted

  2. US 9549913

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Jan 24, 2017 · Expires Jan 19, 2037

    granted

  3. US 9539234

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Jan 10, 2017 · Expires Jan 5, 2037

    granted

  4. US 9458507

    Antipsychotic treatment based on SNP genotype

    VANDA PHARMACEUTICALS INC. · Granted Oct 4, 2016 · Expires Sep 29, 2036

    granted

  5. US 9446038

    Method and composition for treating a serotonin receptor-mediated condition

    VANDA PHARMACEUTICALS INC. · Granted Sep 20, 2016 · Expires Sep 15, 2036

    granted

  6. US 9408839

    Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype

    VANDA PHARMACEUTICALS INC. · Granted Aug 9, 2016 · Expires Aug 4, 2036

    granted

  7. US 9328387

    Antipsychotic treatment based on SNP genotype

    VANDA PHARMACEUTICALS INC. · Granted May 3, 2016 · Expires Apr 28, 2036

    granted

  8. US 9243295

    Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype

    VANDA PHARMACEUTICALS INC. · Granted Jan 26, 2016 · Expires Jan 21, 2036

    granted

  9. US 9212129

    Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide

    VANDA PHARMACEUTICALS INC. · Granted Dec 15, 2015 · Expires Dec 10, 2035

    granted

  10. US 9157121

    Method of treatment based on polymorphisms of the KCNQ1 gene

    VANDA PHARMACEUTICALS INC. · Granted Oct 13, 2015 · Expires Oct 8, 2035

    granted

  11. US 9138432

    Methods for the administration of iloperidone

    VANDA PHARMACEUTICALS INC. · Granted Sep 22, 2015 · Expires Sep 17, 2035

    granted

  12. US 9072742

    Method of predicting a predisposition to QT prolongation

    VANDA PHARMACEUTICALS INC. · Granted Jul 7, 2015 · Expires Jul 2, 2035

    granted

  13. US 9074255

    Method of predicting a predisposition to QT prolongation

    VANDA PHARMACEUTICALS INC. · Granted Jul 7, 2015 · Expires Jul 2, 2035

    granted

  14. US 9074254

    Method of predicting a predisposition to QT prolongation

    VANDA PHARMACEUTICALS INC. · Granted Jul 7, 2015 · Expires Jul 2, 2035

    granted

  15. US 9074256

    Method of predicting a predisposition to QT prolongation

    VANDA PHARMACEUTICALS INC. · Granted Jul 7, 2015 · Expires Jul 2, 2035

    granted

  16. US 9060995

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Jun 23, 2015 · Expires Jun 18, 2035

    granted

  17. US 9057104

    Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype

    VANDA PHARMACEUTICALS INC. · Granted Jun 16, 2015 · Expires Jun 11, 2035

    granted

  18. US 8999638

    Method of treatment based on polymorphisms of the KCNQ1 gene

    VANDA PHARMACEUTICALS INC. · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted

  19. US 8865210

    Stable dosage formulations of imidazolylalkyl-pyridines

    VANDA PHARMACEUTICALS INC. · Granted Oct 21, 2014 · Expires Oct 16, 2034

    granted

  20. US 8785492

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Jul 22, 2014 · Expires Jul 17, 2034

    granted

  21. US 8729100

    Method and composition for treating an alpha adrenoceptor-mediated condition

    VANDA PHARMACEUTICALS INC. · Granted May 20, 2014 · Expires May 15, 2034

    granted

  22. US 8652776

    Prediction of QT prolongation based on SNP genotype

    VANDA PHARMACEUTICALS INC. · Granted Feb 18, 2014 · Expires Feb 13, 2034

    granted

  23. US 8618134

    Method and composition for treating a serotonin receptor-mediated condition

    VANDA PHARMACEUTICALS INC. · Granted Dec 31, 2013 · Expires Dec 26, 2033

    granted

  24. US 8586610

    Methods for the administration of iloperidone

    VANDA PHARMACEUTICALS INC. · Granted Nov 19, 2013 · Expires Nov 14, 2033

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.